A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors
Description
Brief Summary
Study to evaluate the safety and tolerability of the study drug CLN-418, to determine the
maximum tolerated dose and/or recommended Phase 2 study dose of CLN-418.
Detailed Description
This is a study to evaluate the safety and tolerability of the study drug CLN-418, and to
determine the maximum tolerated dose and/or recommended Phase 2 study dose of CLN-418.
The study will also look at the anti-tumor activity, pharmacokinetics and immunogenicity of
CLN-418.The study consists of 2 parts. In Part 1, patients are enrolled into different cohort
doses in order to identify the appropriate recommended phase 2 dose (RP2D) or maximum
tolerated dose (MTD). In Part 2, participants with metastatic / unresectable Non small cell
lung cancer (NSCLC), Triple Negative Breast Cancer (TNBC) will receive the maximum tolerated
dose (MTD) and/or recommended phase 2 dose (RP2D) established in Part 1 of the study. In Part
1 and Part 2, participants will be administered treatment every 3 weeks.
Phase
N/AInclusion and Exclusion Criteria
- Willingness to sign a written informed consent document.
- Male or female subject aged ≥18 years old at the time of screening.
- Histologically or cytologically confirmed advanced solid tumors (e.g., breast cancer, ovarian cancer, endometrial cancer, cervical cancer, squamous cell non-small cell lung cancer (sNSCLC), cholangiocarcinoma, esophagus cancer, urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC)), followed by dose-expansion cohorts (Part 2) of subjects with advanced and/or metastatic non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC).or recurrent and progressed since last antitumor therapy for which no alternative, curative standard therapy exists.
- Adequate organ and bone marrow function.
- Prior used anti-B7H4 and/or anti-4-1BB antibody treatment.
- Immuno-oncology therapy or targeted anti-cancer therapy within 4 weeks prior to first dose of investigational product, any other anti-cancer therapy within 2 weeks prior to first dose of investigational product.
- Not yet recovered from surgery or (immune-related) toxicity related with previous treatment.
- Known history or active infection of hepatitis B or C.
- History of cirrhosis or non-alcohol steatohepatitis, alcohol or drug-related, autoimmune hepatitis.
- Known brain metastases or other central nervous system metastases that are either symptomatic or untreated that require concurrent treatment.
- Active infection that requires treatment with antibiotics or antiviral treatment within 3 weeks prior to first dose of investigational product.
- Known history of infection with human immunodeficiency virus or known acquired immunodeficiency syndrome (AIDS).
- Known autoimmune disease.
- Clinically significant cardiac condition.
- Pregnant or breastfeeding women.
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.